

Cumulative Index 1986

Volume 4

<i>February</i>	RISK FOR DEVELOPING CARDIOVASCULAR RISK FACTORS AND ADVERSE EFFECTS OF RISK FACTOR REDUCTION (pages 3-168)
<i>May</i>	GERIATRIC CARDIOLOGY (pages 175-348)
<i>August</i>	ELECTROPHYSIOLOGIC EVALUATION OF ARRHYTHMIAS (pages 353-569)
<i>November</i>	SILENT MYOCARDIAL ISCHEMIA (pages 577-750)

Note: Page numbers of issue and article titles are in **boldface** type.

- Ablation, and mapping, 503
 catheter, 355
 for cardiac arrhythmias, **543-550**
 for tachycardias, 456
 of accessory extranodal pathways, 545-546
 of atrial tachycardia foci, 546-548
 of AV junction, clinical results of, 544-545
 technique for, 544
 of ventricular tachycardia foci, 548
 rationale for, 543-544
- Accessory pathway(s), and incremental atrial pacing, 368-369
 and ventricular premature stimulation, 379-382
 as bystander, 453
 concealed, 354
 for AV reentry, 438-442
 in Wolff-Parkinson-White syndrome, 450
 drugs that affect, in Wolff-Parkinson-White syndrome, 455-456
 evaluation of electrophysiologic properties of, in Wolff-Parkinson-White syndrome, 452-453
 extranodal, catheter ablation of, 545-546
 in atrial premature stimulation, 372-373
 in preexcitation, 447-448
 latent, in Wolff-Parkinson-White syndrome, 450
 location of, in Wolff-Parkinson-White syndrome, 451
 posteroseptal, ablation of, 546
 retrograde atrial activation in, 375
- Acebutolol, and glucose intolerance, 128
- Activation sequence, and ventricular tachycardia, 462-463
 eccentric atrial, 379
- Activity(ies), daily, silent myocardial ischemia during, **635-642**
 physical, as protective factor against cardiovascular disease, 20
- Adrenergic inhibitors, and hyperlipidemia, 50
- Adrenergic nervous system, in left ventricular hypertrophy, 88
- Adult-onset obesity, as cardiovascular risk factor, 77-78
- Afterload, increased, in left ventricular hypertrophy, 84-88
- Age, advanced, diminished beta-adrenergic modulation of cardiovascular function in, **185-200**. See also *Elderly*, and hypertension, 59
 as cardiovascular risk factor, 10-11
 effect on heart rate response to isoproterenol, 190-194, 196, 199
 effect on renal function, 227-234
- Aging, and hypertension, 204
 and pharmacokinetics, 214-220
 drug absorption and bioavailability in, 218
 drug distribution in body in, 219-220
 effect on arterial pressure, 204-207
 effect on cardiac output, 202-204
 effect on heart rate, 273-275
 effect on norepinephrine levels, during exercise, 202-203
 effect on respiratory mechanisms, 201-202
 effect on responsiveness to catecholamines, 194
 effect on sleep-related breathing disorders, 201-202
 functional dependency in, 311
 hypertension and, pathophysiology of, **235-243**
 in America, a demographic perspective, 175-183
 arthritis and, 179-180
 health care utilization in, 182-183
 hypertension and, 179
 morbidity in, 179-182
 mortality and survival in, 177-179
 oldest old in, 177
 population characteristics of, 175-177
 pharmacodynamic alterations and, 220-223
 physiologic changes in, 213-214
 quality and quantity of life and, 306-310
 sodium and potassium economy in, 208-209
 water homeostasis and, 207-208
- A-H interval, 366
 in AV conduction system disturbances, 389
 jump in, 366

- AICD. See *Automatic implantable cardioverter-defibrillator*.
- Ajmaline, in evaluation of distal AV conduction system, 423
- Alcohol, and coronary heart disease, 21
and hypertension, 60
- Alfalfa, in hyperlipidemia, 100
- Alpha-antagonists, central, and glucose intolerance, 125-126
- Amiloride, and glucose intolerance, 124
- Amiodarone, for AV and AV nodal reentry, 444
for ventricular arrhythmias, 294-296
for ventricular tachycardia, 396
ability of electrophysiologic tests to predict prognosis in, 482-483
for Wolff-Parkinson-White syndrome, 456
incidence of proarrhythmia due to, 494
- Amphetamines, and heart, 154-155
- Aneurysm, ventricular, as complication of acute myocardial infarction, in elderly, 260
- Angina, demand, treatment of, 702-703
effort, detection of silent myocardial ischemia in patients with, using continuous electrocardiographic monitoring, 627-632
mechanisms of transient ischemia in ambulatory patients with, 631
- Heberden's, 698
in elderly, clinical presentation of, 254
management of, 257-258, 309
- Maseri's mixed, 698
- Prinzmetal's, 698
- rest, as result of coronary artery spasm, ambulatory electrocardiographic studies in, 639-640
spontaneous, mechanisms of, 698-699
stable effort, ambulatory electrocardiographic studies in, 636-637
unstable, ambulatory electrocardiographic studies in, 637-639
- Angina pectoris, as symptom of silent myocardial ischemia, 579
during daily activities, silent myocardial ischemia and, 635-642
electrocardiographic monitoring for, and ischemia, 618
reproduction of, in response to exercise testing, 712
severity of, and coronary artery disease, 622-624
silent myocardial ischemia and, 622
treatment of, objective assessment of, 690-691
types of, in ischemic syndromes, 697-698
with recognized vs. unrecognized myocardial infarctions, in Framingham Heart Study, 586-587
- Angiography, coronary, in elderly, 309
- Angioplasty, transluminal coronary, in elderly, 309-310
- Angiotensin, in left ventricular hypertrophy, 88
- Antegrade conduction, in accessory AV connection, 450
- Antiarrhythmic drug(s), for elderly, 285-303. See also specific drugs.
- Antiarrhythmic therapy, use of electrophysiologic studies for, 355
- Antitachycardia device(s), implantable, for termination of tachycardias, 535
- Antitachycardia pacing, long-term, with implantable devices, 534
- Antihypertensive drugs, and glucose intolerance, 117-135
and heart, 155
and hyperlipidemia, 49-50
and left ventricular hypertrophy, 141-142
- Anorectic drugs, and heart, 154-155
- Aortic impedance, exercise and, 194
- Aortic regurgitation, in elderly, 265-266
- Aortic stenosis, in elderly, 263-265
- Aortic valve disease, in elderly, 263-267
- Apolipoproteins, and atherosclerosis, 48
and hyperlipidemia, 51-52
- Aprindine, incidence of proarrhythmia due to, 494
- Arc of block concept, 531
- Arrhythmia(s). See also specific types of arrhythmias.
and risk modification, 156-158
antiarrhythmic drug treatment for, 285-303
catheter ablation for, 543-550
clinical aspects of, 273-283
electrophysiologic evaluation of, issue on, 353-369
left ventricular hypertrophy and, 138-139
mechanisms and diagnosis of, 565-566
mechanisms of, as determined by electrophysiologic studies, 461-463
role of autonomic nervous system in, 461
nonclinical, 360
reperfusion, in sudden cardiac death, 602
sinus, and atrial premature stimulation, 407
ventricular. See *Ventricular arrhythmia(s)*.
- Arrhythmia death, and coronary artery disease, 10
- Arrhythmogenic right ventricular dysplasia, in children, 559
- Arterial pressure, changes in, in elderly, 204-207
in response to upright posture, 205-206
- Arteriosclerotic heart disease, 253-261. See also *Coronary artery disease*.
- Artery(ies). See also *Atherosclerosis* and *Coronary artery disease*.
injury to lining of, and atherogenesis, 8-9, 71
plaques in, in children, 34
- Arthritis, aging and, 179-180
- Artifact, role of, in prospective arrhythmia evaluation, 510-511
- Atenolol, and glucose intolerance, 128
- Atherosclerosis, and left ventricular hypertrophy, 140
and risk factors, 8-10
coronary. See *Coronary artery disease*.
in children, 34
- Atrial electrogram, fractionation of, 368
- Atrial endocardial mapping, in Wolff-Parkinson-White syndrome, 452
- Atrial fibrillation, digoxin for, 298-299
in atrial pacing, 368
- Atrial flutter, 354
digoxin for, 299
in children, electrophysiologic study of, 553-554
- Atrial flutter-fibrillation, assessment of, in Wolff-Parkinson-White syndrome, 453
induction of, in accessory pathway, 368
- Atrial overdrive suppression, pacing protocol for, 404-405
- Atrial premature stimulation, 369-373
measurement of sinoatrial conduction time with, Strauss method for, 405-410
- Atrial vulnerable period, 372
- Atriofascicular tract(s), 448
- Atrioventricular block, high-grade, 389
history of, 417-418
in children, electrophysiologic study of, 554-556
in chronic bifascicular block, 426
in elderly, evaluation of, 280-281
- Mobitz I, in syncope, 519
- second-degree, 389
spontaneous second- or third-degree, H-V interval and, 419
- Atrioventricular conduction, evaluation of, electrical activity in, 354
in syncope, 518-520
intermittent (second-degree AV block), 389
- Atrioventricular conduction system, distal, function of, 417-428
history of, 417-418
disturbances of, evaluation of, 389

- Atrioventricular connection, accessory, antegrade conduction in, 450
- Atrioventricular junction, catheter ablation of, 548
clinical results of, 544-545
technique for, 544
- Atrioventricular junctional rhythm(s), evaluation of, 279
- Atrioventricular muscle connection(s) (typical Kent bundles), in preexcitation, 448
- Atrioventricular nodal conduction, 389
- Atrioventricular nodal pathways, dual, 431-432
- Atrioventricular nodal Wenckebach phenomenon, 366
- Atrioventricular node, and atrial premature stimulation, 369-370
and incremental atrial pacing, 366
and incremental ventricular pacing, 373-374
and ventricular premature stimulation, 379
drugs with predominant effect on, in Wolff-Parkinson-White syndrome, 455
functional refractory period and effective refractory period values of, clinical relevance of, 370
- Atrioventricular reentrant tachycardias, 392
- Atrium(a), and atrial premature stimulation, 372
and incremental atrial pacing, 368
and incremental ventricular pacing, 375
and ventricular premature stimulation, 382-383
effective refractory period of, 369, 372
functional refractory period of, 369, 372
- Atropine, to determine sinus node function, 404
- Automatic implantable cardioverter-defibrillator (AICD), 537
- Automatic implantable defibrillator, for ventricular tachycardia, 396
- Automaticity, definition of, 401
- Autonomic tone, 402
- AV. See *Atrioventricular*.
- Beta-adrenergic blockade, and aortic input impedance during exercise, 194
effect on cardiac output and heart rate during exercise, in elderly, 189-190
- Beta-adrenergic blocking agents, in treatment of silent myocardial ischemia, 687-688
in Wolff-Parkinson-White syndrome, 455
- Beta-adrenergic modulation, diminished, of cardiovascular function, in elderly, 185-200
- Beta-adrenergic stimulation, effect on myocardial contraction, 194-199
- Beta-blockers, and glucose intolerance, 127-128
and heart, 155-156
and hyperlipidemia, 50
and risk modification, 159
following myocardial infarction, in elderly, 257
for angina, in elderly, 309
for hypertension, in elderly, 248-249
for ventricular arrhythmias, in elderly, 293-294
for Wolff-Parkinson-White syndrome, 393-394
incidence of proarrhythmia due to, 494
- Bethanidine, for inducible ventricular fibrillation, 482
for ventricular tachycardia, electrophysiologic results of, 482
incidence of proarrhythmia due to, 494
- Bifascicular block, 389, 417
chronic, 422
associated heart disease and, 423-424
asymptomatic patients and, 426
AV block in, 426
current perspective on, 423-426
H-V interval and, 424-426
mortality in, 425
- mortality and, 424
role of electrophysiologic studies in, 426-427
syncope in, 426
unexplained, 424
- Bilateral block, in His-Purkinje system, 370-371
- Bile acid sequestrant resins, in hyperlipidemia, 99
- Bioavailability, definition of, 218
drug absorption and, 218-219
- Biosensor(s), in prevention of tachycardias, 528
- Blood flow, pulsatile, and left ventricular hypertrophy, 86
- Blood pressure, diastolic, effect of decline in, 7-8
elevated, as cardiovascular risk factor, 18, 57-66
estrogen and, 146
in children, 34-39
in response to exercise testing, 711-712
left ventricular hypertrophy and, 84
obesity and, 76-77
progestins and, 147
- Blood viscosity, in hypertension, 88-89
- Body composition, changes in, in elderly, 214
- Borderline hypertension, definition of, 57-58
- Bradyarrhythmia, silent myocardial ischemia and, 601
- Bradycardia, sinus, and cardiac disease, in elderly, 274-275
persistent, electrophysiologic evaluation of AV conduction system function in, 388
- Brady-tachy syndrome, 516
electrophysiologic studies for, 413
- Bretylium, for ventricular arrhythmias, 296-297
- Bumetanide, glucose intolerance and, 124
- Bundle branch block, 370
in His-Purkinje system, 368
- Bundle branch reentry, 376
- Caffeine, and hypertension, 60
- Calcification, mitral annular, in elderly, 268-269
- Calcium antagonists, and glucose intolerance, 129
in treatment of silent myocardial ischemia, 688-690
in Wolff-Parkinson-White syndrome, 455
- Calcium-channel blockers, and heart, 155-156
for angina, in elderly, 309
for hypertension, in elderly, 249
for ventricular arrhythmias, in elderly, 297-299
for Wolff-Parkinson-White syndrome, 393
- Cancer, of colon, cholesterol and, 95-96
of endometrium, estrogen and, 149
- Captopril, and glucose intolerance, 128
for hypertension, in elderly, 250
- Cardiac arrest. See also *Sudden cardiac death*.
out-of-hospital, electrophysiologic evaluation after, 355
programmed stimulation for, 397-398
- Cardiac output, aging and, 202-204
in elderly hypertensives, 236-237
in response to exercise, in elderly, 185-200
regulation of, role of vasculature in, 333-348
- Cardiac pain, pathway of, 727
role of endorphins in, 731-732
theories of, 727-728
threshold and perception of, clinical studies of, 728-731
- Cardiac rupture, as complication of acute myocardial infarction, 260
- Cardiac surgery, in elderly, 310
- Cardiokymography, in assessment of asymptomatic patients with positive exercise tolerance tests, 720
- Cardiology, geriatric, issue on, 175-348
- Cardiomyopathy, hypertrophic, 266-267
- Cardiovascular disease. See also *Coronary artery disease*.
aging and, 177-180
epidemiology of, 305-306
oral contraceptives and, 147-148, 150

Cardiovascular disease (*Continued*)

- prevalence of, in diabetes, 67-68
- risk factors for, adverse effects of antihypertensive therapy on, 105-115
 - adverse effects of hyperlipidemic treatment on, 95-103
 - effects of hormonal therapy on, 145-152
 - identification and relative weight of, 3-32
 - modification of, ethical issues in, 163-168
 - reduction of, negative effects on heart, 153-161
 - risk of development of and adverse effects of risk factor reduction, issue on, 3-168
- Cardiovascular function, diminished beta-adrenergic modulation of, in elderly, 185-200
- Cardioversion, synchronized transvenous, of ventricular tachycardia, 536
 - defibrillation and, transvenous, 536-537
- Carotid hypersensitivity syndrome, and syncope, 520
- Carotid sinus massage, in syncope, 520
- Catecholamine(s), effect on exercise, in elderly, 185-200
 - in left ventricular hypertrophy, 88, 140
- Catheter(s), in electrophysiologic studies, 357
- Chemical denervation, 388
- Chest pain, myocardial ischemia and, 621-625
 - metabolic myocardial function and, electrocardiographic changes and, 621-622
 - supply/demand ratio imbalance and, 621
 - reproduction of, in response to exercise testing, 712
- Children, cardiovascular risk factors in, 33-46
 - invasive electrophysiologic studies in, 551-563
 - left ventricular hypertrophy in, 139-140
 - target organ changes in, 34
- Chlorthalidone, and glucose intolerance, 123
- Cholesterol, as cardiovascular risk factor, 21, 13-16, 47-56
 - in children, 34, 39-41
 - obesity and, 75-76
 - reduction of, 7, 95-103
- Cholestyramine, in hyperlipidemia, 99
- Cibenzoline, incidence of proarrhythmia due to, 494
 - renal clearance of, 215-216
- Cigarettes. See *Smoking and Tobacco*.
- Clofibrate, adverse effects of, 98
 - and heart, 154
 - and hyperlipidemia, 50-51
- Clonidine, and glucose intolerance, 125
 - for hypertension, 249
- Coagulation factors, hormones and, 146-147
- Cold pressure test, and hypertension, 62
- Colestipol, in hyperlipidemia, 99
- Colon, cancer of, cholesterol and, 95-96
 - hypolipidemic drugs and, 98
- Compactin, in hyperlipidemia, 99
- Computed tomography, for detection of syncope, 515
- Contraceptives, oral. See *Estrogen, Oral contraceptives, and Progestin*.
- Contraction abnormalities, regional, as markers of myocardial ischemia, 682
- Coronary angiography, in elderly, 309
- Coronary artery(ies), spasm of, and sudden cardiac death, 602
- Coronary artery bypass surgery, in elderly, 310
 - in treatment of silent myocardial ischemia, 692-693
- Coronary artery disease, ambulatory monitoring of, ST segment in, 662-663
 - and left ventricular hypertrophy, 140
 - asymptomatic, and predisposition to myocardial infarction, 644
 - detection of, by regional ejection fraction during exercise, 677-684
 - determination of post-exercise-test likelihood of, 706-707
 - in elderly, 253-261
 - cardiac investigations for, 255-256
 - clinical presentation of, 254-255
 - management of, 256-260, 309-310
 - pathology and pathophysiology of, 254
 - physical examination for, 255
 - prevalence and incidence of, 253-254
 - prevention of, 22
 - severe, treatment of asymptomatic patients with positive exercise studies and, 721-722
 - symptomatic, silent myocardial ischemia in, and acute myocardial infarction, 645-651
- Coronary artery spasm, as cause of rest angina, ambulatory electrocardiographic studies in, 639-640
- Corrected sinus node recovery time (CSNRT), 388
- Death, arrhythmia, and coronary artery disease, 10
 - following electrophysiologic studies, 358
 - sudden cardiac. See *Sudden cardiac death*.
- Defibrillation, and transvenous cardioversion, 536-537
- Diabetes, and hypertension, 119
 - and left ventricular hypertrophy, 140
 - antihypertensive drugs and, 117-135
 - as cardiovascular risk factor, 20, 67-74
 - silent myocardial ischemia and, 586
- Diastole, left ventricular, in hypertension, 89-90
- Diazoxide, and glucose intolerance, 127
- Diet, and cardiovascular disease, 21-22
 - and hyperlipidemia, 48-49, 96-97
 - and hypertension, 59-60
 - weight loss, and heart, 155
- Digitalis, for AV reentry, 444
 - for children with Wolff-Parkinson-White syndrome, 557
- Digoxin, for supraventricular arrhythmias, in elderly, 298-299
 - for Wolff-Parkinson-White syndrome, 393-394
 - renal clearance of, in elderly, 215
- Diltiazem, and glucose intolerance, 129
- Disopyramide, for arrhythmias, in elderly, 289-290
 - for ventricular tachycardia, electrophysiologic results of, 480
 - incidence of proarrhythmia due to, 494
 - volume of distribution of, 219-220
- Diuretics, and glucose intolerance, 120-125
 - and hyperlipidemia, 50
 - and risk modification, 158-159
- Drug(s). See also specific agents and types of drugs.
 - and hyperlipidemia, 49-51
 - antihypertensive, and glucose intolerance, 117-135
 - and left ventricular hypertrophy, 141-142
 - cardiovascular, age-related alterations of, 223
 - pharmacodynamic alterations in, in elderly, 220-223
 - pharmacokinetics of, in elderly, 214-220
 - rational use of, in elderly, 222-223
 - hypolipidemic, 97-100
 - that affect accessory pathway, in Wolff-Parkinson-White syndrome, 455-456
 - with predominant effect on AV node, in Wolff-Parkinson-White syndrome, 455
- Drug distribution, and drug half-life, in elderly, 220
 - in body, in elderly, 219-220
- Drug tests, provocative, in evaluation of distal AV conduction system function, 423
- Dysbetalipoproteinemia, familial, and atherosclerosis, 51-52
- Dyslipidemias, normolipidemic, and atherosclerosis, 48
- Dysplasia, arrhythmogenic right ventricular, in children, 559
- Dysrhythmias, detection of, accuracy of electrocardiogram in, 742

- Eccentric retrograde activation, in supraventricular tachycardia, 453
- Echocardiography, exercise, in assessment of asymptomatic patients with positive exercise tolerance tests, 719-720
- for diagnosis of coronary artery disease, 256
- in hypertension, 81-83, 89
- Effective refractory period, of atrium, 369, 372
- of AV node, 370
- of fast AV nodal pathway, 369
- of His-Purkinje system, 371
- Ejection fraction, regional. See *Regional ejection fraction*.
- Elderly, arrhythmias in, antiarrhythmic drug treatment for, 285-303
- clinical aspects of, 273-283
- arteriosclerotic heart disease in, 253-261
- coronary artery disease in, management of, 309-310
- diminished beta-adrenergic modulation of cardiovascular function in, 185-200
- functional dependency of, 311
- homeostatic fragility in, 201-211
- hypertension in, pathophysiology of, 235-243
- structural cardiac adaptation and, 237
- treatment for, 245-252
- in America, a demographic perspective, 175-183. See also *Aging, in America*.
- quality and quantity of life of, 306-310
- renal function in, 227-234. See also *Kidney(s)*.
- results of reduced fluid intake in, 207-208
- sodium and potassium balance in, 208-209
- tissue oxygenation in, 201-207
- valvular heart disease in, 263-271
- water and electrolyte environment in, 207-209
- Electrocardiogram, continuously monitored, potential for real-time processing of, in detection, quantitation, and intervention of silent myocardial ischemia, 735-745
- Electrocardiographic monitoring, ambulatory. See also *Electrocardiographic monitoring, dynamic and Holter monitoring, 24-hour*.
- after myocardial infarction, in prospective evaluation of ventricular tachycardia, 507
- continuous, in assessment of asymptomatic patients with positive exercise tolerance tests, 719
- potential for real-time processing of, in detection of silent myocardial ischemia, 735-745
- for assessment of silent ischemic events, 686
- for assessment of therapy in silent ischemia patients, 632
- in evaluation of syncope, 515
- long-term, feasibility of, to individualize therapy for coronary artery disease, 742-744
- of ST segment, 660-665
- to characterize ischemic heart disease out of hospital, 659-668
- continuous, for detection of silent myocardial ischemia in effort angina patients, 627-632
- in identification of ventricular arrhythmias during postinfarction period, 656
- dynamic. See also *Electrocardiographic monitoring, ambulatory and Holter monitoring, 24-hour*.
- in diagnosis and therapy of ventricular tachycardia, 395
- in evaluation of patients at high risk for sudden cardiac death, 397
- in sinus node dysfunction, 387-388
- in syncope of undetermined etiology, 391
- of supraventricular tachycardia, 391
- for assessment of myocardial ischemia, 595-600
- for diagnosis of coronary artery disease, in elderly, 255-256
- Electrocardiographic recordings, identification of ischemia episodes from, 629
- Electrocardiographic studies, ambulatory, for silent myocardial ischemia, in asymptomatic patients, 640
- in patients with rest angina, 639-640
- in patients with acute myocardial infarction, 653
- in patients with stable effort angina, 636-637
- in patients with unstable angina, 637-639
- Electrocardiography, His bundle. See *His bundle electrocardiography*.
- in hypertension, 81-83
- Electroencephalogram, for detection of syncope, 515
- Electrogram, atrial, fractionation of, 368
- Electrophysiologic response(s), normal, of human heart, 365-366
- Electrophysiologic studies. See also *Electrophysiologic testing*.
- alternatives to, 360-361
- complications of, 357-358, 468
- cost-effectiveness of, 358
- economics and, 358
- in children, 551-563
- indications for, 387-400
- intracardiac, technique of, 554
- performance of, 356-357
- positive, criteria for, 467-468
- reliability of for predicting drug efficacy, 468
- reproducibility of, 359
- Electrophysiologic testing. See also *Electrophysiologic studies*.
- noninvasive perspective on, 565-569
- proarrhythmic criteria in, 489
- proarrhythmic responses during, 487-496
- vs. Holter monitoring, advantages and disadvantages of, 568
- Electrophysiology, clinical cardiac, history, rationale, and future of, 353-364
- limitations and problems in, 358-360
- interventional, 355-356
- catheter ablation, 543-550
- Enalapril, for hypertension, in elderly, 250
- Encainide, for ventricular arrhythmias, in elderly, 292-293
- for ventricular tachycardia, electrophysiologic results of, 481
- in Wolff-Parkinson-White syndrome, 456
- incidence of proarrhythmia due to, 494
- Endometrium, cancer of, estrogen and, 149
- Endorphins, role of, in cardiac pain responses, 731-732
- Endothelium, arterial, in diabetes, 71-72
- Entire recovery time. See also *Total recovery time*.
- in electrophysiologic evaluation of sinus node dysfunction, 402, 404
- Entrainment, and arrhythmias, 461-462
- in pacemaker termination of tachycardias, 531-532
- vs. overdrive pacing, 462
- Environmental factors, and hypertension, 59-61
- Epicardial mapping, and ventricular preexcitation, 447
- Epinephrine, effect of exercise on, 187, 190, 192
- Erythrocyte sedimentation rate, as risk factor, 21
- Estrogen, and hyperlipidemia, 49
- and hypertension, 60-61
- effects of as oral contraceptive and menopausal therapy, and health impacts of reduction of, 145-152
- obesity and, 76-77
- Ethacrynic acid, and glucose intolerance, 123-124
- Ethical issues, in risk factor modification, 163-168
- Etiology, and hyperlipidemia, 50
- European Study Group for Preexcitation, 448
- Event recorder(s), to monitor electrocardiogram, 387

- Exercise, and heart, 154
 and hyperlipidemia, 97
 and hypertension, 62
 and modification of cardiovascular risk factors, 156-158
 effect on cardiac output and heart rate, 185-200, 202-204
 regional ejection fraction during, to identify coronary artery disease, 677-684
- Exercise testing, after myocardial infarction, 653-654
 for diagnosis of coronary artery disease, in elderly, 256
 in women, 707-708
 role of, in asymptomatic post-myocardial infarction patients, 711
 in identification of silent myocardial ischemia, 705-715
 determination of post-test likelihood of coronary artery disease, 706-707
 subjects for, 712-714
 role of thallium-201 scintigraphy in, 654-655
 ST-segment response in, modifiers of, 707
 to assess effect of treatment for silent myocardial ischemia, 686
 variables in interpretation of, 711-712
 vs. ambulatory monitoring, in detection of ischemia, 627-628
- Exercise tolerance test, positive, in asymptomatic patients, 717-726
 prognostic and diagnostic significance of, 717-718
 in asymptomatic patients with severe coronary artery disease, 721-722
- Extrastimulation, and arrhythmias, 461
 in prevention of tachycardias, 527
- Extrastimuli, multiple, in pacemaker termination of tachycardias, 531
 number of, for arrhythmia induction, 474
 in ventricular stimulation, 466
- Familial dysbetalipoproteinemia, and atherosclerosis, 51-52
- Familial hypercholesterolemia, and atherosclerosis, 51
- Family history. See also *Genetic factors*.
 as cardiovascular risk factor, 11-13
- Fascicle(s), block in, 417
- Fasciculoventricular connection(s), 454
 in preexcitation, 448
- Fasciculoventricular pathway, 354
- Fat, body, in children, 41-43
 dietary, and hyperlipidemia, 96
 as cardiovascular risk factor, 21
- Fibrillation, atrial. See *Atrial fibrillation*.
 ventricular. See *Ventricular fibrillation*.
- Fibrinogen, elevated, as cardiovascular risk factor, 20
- Flecainide, for ventricular arrhythmias, in elderly, 292
 for ventricular tachycardia, electrophysiologic results of, 481
 incidence of proarrhythmia due to, 494
- Fluorocopy, cardiac, in assessment of asymptomatic patients with positive exercise tolerance tests, 720-721
- Framingham Heart Study, electrocardiographic left ventricular hypertrophy vs. myocardial infarction in, 588
 incidence of angina pectoris in myocardial infarctions in, 586-587
 silent myocardial ischemia and infarction in, 583-591
 incidence of, 583-584
 mortality in, 588-589
 preventive interventions in, 589-590
 recurrences and other morbidity of, 587-588
 silent myocardial ischemia in, predisposing factors for, 585-586
 unrecognized myocardial infarction in, 585
- Free fatty acids, in obesity, 77-78
- Functional dependency, of elderly, 311
- Functional refractory period, of atrium, 369, 372
 of AV node, 369
 of slow AV nodal pathway, 369
- Furosemide, and glucose intolerance, 123
- Fusion atrial activation, 375
- Gallstones, weight loss and, 96
- Ganglionic neuron inhibitors, and glucose intolerance, 126-127
- Gemfibrozil, in hyperlipidemia, 98
- Genetic factors. See also *Family history*.
 and hyperlipidemia, 51-53
 and hypertension, 58-59
 in glucose intolerance, 69
- Geographic factors, in glucose intolerance, 69
- Geriatric cardiology. See also entries under *Aging and Elderly*.
 issue on, 175-312
 therapeutic goals of, 305-312
- Glucose intolerance, antihypertensive drugs and, 117-135
 as cardiovascular risk factor, 67-74
 genetic factors in, 69
 geographic factors in, 69
 hormones and, 146-147
 obesity and, 75
- Gout, and left ventricular hypertrophy, 140
- Guanabenz, and glucose intolerance, 126
- Half-life, drug, definition of, 220
- Health care utilization, aging and, 182-183
 human, normal electrophysiologic responses of, 365-386
 risk modification and, 156
 negative effects of, 153-161
 structural adaptation of, in elderly, and hypertension, 237
- Heart disease, and chronic bifascicular block, 423-424
 angina pectoris and, severity of, 622-624
 transient ST-T-wave alterations and, 617-619
- Heart failure, congestive, as complication of acute myocardial infarction, in elderly, 259
 in myocardial infarction, in Framingham Heart Study, 587-588
- Heart rate, in elderly, changes in, 202-207
 evaluation of, in cardiac disease, 273-275
 in response to exercise, 185-200
 in response to exercise testing, 712
- Hematocrit, in hypertension, 88-89
- Hemodynamics, and left ventricular hypertrophy, 139-140
- Hemoglobin, in hypertension, 88-89
- Hepatic drug clearance, in aging, 216-218
- Hepatic function, changes in, in elderly, 214
- High-density lipoprotein(s), as protective factor against cardiovascular disease, 16-17, 47-48
 estrogen and, 146
 in children, 39-41
 in weight loss, 96
- His bundle, retrograde activation of, 375
- His bundle electrocardiography, history of, 353
 AV conduction disturbances during, 360
- His bundle potential, 353
- His-Purkinje conduction, 389
- His-Purkinje system, and atrial premature stimulation, 370-372

- and incremental atrial pacing, 366-368
and incremental ventricular pacing, 374-375
and ventricular premature stimulation, 376-379
effective refractory period of, 371
refractoriness of, 371, 390
- History, family, as cardiovascular risk factor, 11-13
- Holter monitoring, for detection of syncope, 515
for evaluation of antiarrhythmic drug efficacy, 488
in acute myocardial infarction, 507
in chronic left ventricular dysfunction, 509
24-hour. See also *Electrocardiographic monitoring, ambulatory* and *Electrocardiographic monitoring, dynamic*.
after myocardial infarction, in prospective evaluation of ventricular tachycardia, 507
continuous, in identification of ventricular arrhythmias during postinfarction period, 656
for assessment of myocardial ischemia, 595-600
transient ST-T-wave alterations on, effect of on coronary artery disease, 617-618
vs. electrophysiologic testing, advantages and disadvantages of, 568
- Homeostasis, definition of, 201
water, and aging, 207-208
- Homeostatic fragility, in elderly, 201-211
- Hormonal therapy, reduction of, effects of, 145-152
- Hormones. See also *Estrogen*, *Oral contraceptives*, and *Progesterone*.
and hyperlipidemia, 49
and hypertension, 60-61
obesity and, 76-77
- H-Q interval. See also *H-V interval*.
lengthened, in bifascicular block, 420
- H-V interval, 366, 417
and chronic bifascicular block, 424-426
in AV conduction, in syncope, 518
in AV conduction system disturbances, 390
markedly prolonged, 425
measurement of, 418-422
controversy about value of, 418-421
prolongation of, 419
- Hyperapobetalipoproteinemia, and atherosclerosis, 52-53
- Hypercholesterolemia, as cardiovascular risk factor, 47-56
- Hyperestrogenemia, obesity and, 76-77
- Hyperglycemia, and coronary heart disease, 117-119
as cardiovascular risk factor, 67-74
- Hyperlipidemia, and atherogenesis, 9
as cardiovascular risk factor, 13-18, 47-56
in children, 39-41
in glucose intolerance, 71
obesity and, 75-76
reduction of, adverse effects of, 95-103
- Hyperlipoproteinemia, and coronary heart disease, 117-119
- Hypertension, aging and, 179, 204
and coronary heart disease, 117-119
and diabetes, 119
and humoral changes, in elderly, 240
and reflex changes, in elderly, 240-241
and sleep-related breathing disorders, in elderly, 206-207
and vascular changes, in elderly, 237-238
angiotensin-converting enzyme inhibitors for, in elderly, 250
as cardiovascular risk factor, 18, 57-66, 81-93
beta-blockers for, in elderly, 248-249
borderline, definition of, 57-58
calcium-channel blockers for, in elderly, 249
central and peripheral blockers of sympathetic nervous system for, in elderly, 249-250
combination therapy for, in elderly, 249
definition of, 235, 245
hemodynamics of, 236-237
in children, 34-39
in glucose intolerance, 71
left ventricular hypertrophy in, 137-139
obesity and, 76-77
pathophysiology of, 235-243
renal characteristics of, 238-239
smoking and, 60
snoring and, 206
structural cardiac adaptation and, 237
thiazide diuretics for, in elderly, 247-248
treatment for, 245-252
results of studies on, 245-247
- Hypertrophy, left ventricular. See *Left ventricular hypertrophy*.
- Hypoglycemic drugs, oral, and heart, 155
- Hypolipidemic drugs, and heart, 154
and hyperlipidemia, 50-51
- Hypotension, due to bretylium, 296
postural, due to nifedipine, 309
- Ileal bypass, partial, in hyperlipidemia, 100
- Impact fraction, in evaluation of cardiovascular risk factors, 7-8
- Implantable electrophysiologic laboratory, 535
- Implantable internal cardioverter, for ventricular tachycardia, 396
- Indapamide, and glucose intolerance, 124
- Indecainide, incidence of proarrhythmia due to, 494
- Infranodal block, during atrial pacing, in syncope, 518
- Inhibition, in prevention of tachycardias, 527-528
- Injury, to arterial endothelium, and atherogenesis, 8-9, 71
- Insulin, and atherosclerosis, 72
- Intra-atrial block, in atrial pacing, 368
- Intra-His conduction abnormalities, 390
- Intraventricular conduction system, 417
- Intrinsic heart rate (IHR), 388
- Ischemia, myocardial, silent. See *Silent myocardial ischemia*.
recurrent, myocardial infarction and, 644-645
- Ischemic gap, 622
- Ischemic syndrome(s), definition of, 697-698
- Isoproterenol, and left ventricular hypertrophy, 140
effect on heart rate response in elderly, 190-194, 196, 199
for increasing sinus node rate, 388
for induction of ventricular tachycardia, 523
for ventricular stimulation, 466
- Isoproterenol resistance, aging and, 220-221
- Isotretinoin, and hyperlipidemia, 50
- Isovolumic relaxation time, in hypertension, 89
- Kent, and AV connections, 447
- Kent bundle, in incremental atrial pacing, 368-369
- Kidney(s), aging, anatomic abnormalities of, 227-228
clinical consequences of, 232
drug clearance from, 214-216
functional abnormalities of, 213-214, 228-231
function of, 227-234
- Labetalol, and glucose intolerance, 128
- Left atrial emptying index, in hypertension, 89
- Left ventricular dysfunction, chronic, prospective evaluation of, using electrophysiologic techniques, 509

- Left ventricular dysfunction (*Continued*)
 programmed stimulation for, 398
 silent myocardial ischemia and, 601
- Left ventricular hypertrophy, and hypertension, 81-93
 and risk factor modification, 158-159
 as cardiovascular risk factor, 137-144
 electrocardiographic, vs. myocardial infarction, in Framingham Heart Study, 588
 in children, 34
- Lidocaine, for cardiac arrhythmias, in elderly, 290
 for ventricular tachycardia, 476
 electrophysiologic results of, 480
 hepatic clearance of, in elderly, 216-218
 incidence of proarrhythmia due to, 494
- Lipids, in children, 39-41
- Lipoprotein(s). See also *Hyperlipidemia*.
 and atherogenesis, 9
 high-density. See *High-density lipoprotein(s)*.
 low-density. See *Low-density lipoprotein(s)*.
 metabolism of, hormones and, 146-147
 very-low-density, in children, 39-41
- Liver, drug clearance from, in elderly, 216-218
 function of, changes in, in elderly, 214
- Logistic regression, in evaluation of cardiovascular risk factors, 5-6
- Loop diuretics, and glucose intolerance, 123-124
- Lorcainide, incidence of proarrhythmia due to, 494
- Low-density lipoprotein(s), as cardiovascular risk factor, 13-16, 21, 47-56
 estrogen and, 146
 in children, 34, 39-41
 in weight loss, 96
- Low-density lipoprotein receptor pathway, mutation in, and hyperlipidemia, 51
- Mahaim fibers, 448
- Mapping, activation, 497-499
 atrial endocardial, in Wolff-Parkinson-White syndrome, 452
 concept of, 497
 endocardial, in Wolff-Parkinson-White syndrome, 451
 ventricular, 396
 fragmentation, 499
 isopotential, 499
 of ventricular arrhythmias, 497-505
 pace, 500-501
- Mechanical stimulation, cardiac responses to, 383-385
- Medication(s), effects of on sinus node function, electrophysiologic tests for, 413
- Menopausal therapy, effects and health impacts of, 145-152
- Mental arithmetic test, and hypertension, 62
- Methyldopa, and glucose intolerance, 126
 for hypertension, in elderly, 249
- Metoprolol, and glucose intolerance, 128
- Mevinolin, in hyperlipidemia, 99
- Mexiletine, for arrhythmias, in elderly, 291-292
 for ventricular tachycardia, 396
 electrophysiologic results of, 480
 incidence of proarrhythmia due to, 494
- Mitral annulus, calcification of, in elderly, 268-269
- Mitral regurgitation, in elderly, 268-269
 as complication of acute myocardial infarction, in elderly, 260
- Mitral stenosis, in elderly, 267-268
- Mitral valve disease, in elderly, 267-269
- Mitral valve prolapse, in elderly, 269
- Mobitz I AV block, in syncope, 519
- Monitoring, electrocardiographic. See *Electrocardiographic monitoring*.
 transtelephone, and tachycardia, 535
- Myocardial contractility, effect of aging on, 202
 effect of beta-adrenergic stimulation on, 194-199
- Myocardial fibrosis, left ventricular hypertrophy and, 137-138
- Myocardial infarction, acute, ambulatory electrocardiographic studies in, 653
 incidence and significance of silent myocardial ischemia after, 651-653
 in elderly, complications of, 259-260
 management of, 258-260
 in relation to silent myocardial ischemia, 643-658
 prognosis factors in, 260
 prospective evaluation of, using electrophysiologic techniques, 507-509
 ambulatory electrocardiographic monitoring after, in prospective evaluation of ventricular tachycardia, 507
 asymptomatic, exercise testing in, 711
 asymptomatic coronary artery disease and predisposition to, 644-645
 exercise testing following, 653-654
 in elderly, clinical presentation of, 255
 oral contraceptives and, 147-148
 recurrent ischemia and, 644
 unrecognized, in Framingham Heart Study, 585
 vs. electrocardiographic left ventricular hypertrophy, in Framingham Heart Study, 588
- Myocardial injury, acute, in development of ventricular arrhythmias, 460
 chronic, in development of ventricular arrhythmias, 460-461
- Myocardial ischemia, ambulatory, new reasons to measure, 659-660
 chest pain and, 621-625
 influence of, on morphologic findings in sudden cardiac death, 607-615
 regional contraction abnormalities as markers of, 682
 reversible, transient ST-segment depression as manifestation of, 628-629
 silent. See *Silent myocardial ischemia*.
 ST segment as measure of, 660
 transient, monitoring of, 665-666
- Nadolol, and glucose intolerance, 128
- Narula method, for measurement of sinoatrial conduction time, 402, 410
- Neomycin, in hyperlipidemia, 99
- Nervous system, adrenergic, in left ventricular hypertrophy, 88
- Neuron inhibitors, ganglionic, and glucose intolerance, 126-127
- Nicotinic acid, in hyperlipidemia, 98-99
- Nifedipine, and glucose intolerance, 129
 for angina, in elderly, 257-258, 309
- Nitrate(s), for angina, in elderly, 309
 in treatment of silent myocardial ischemia, 690
- Nitroglycerin, for left ventricular dysfunction, 674
 transdermal, in treatment of silent myocardial ischemia, 697-704
- Nodoventricular connections, 454
 in preexcitation, 448
- Nodoventricular pathway, 354
- Norepinephrine, effect of exercise on, 187, 190, 192
 plasma, changes in, in elderly, 202-207
- Normolipidemic dyslipidemias, and atherosclerosis, 48
- Nutrition. See *Diet*.

- Obesity, and hypertension, 59
 and left ventricular hypertrophy, 140
 as cardiovascular risk factor, 20, 75-80
 in children, 41-43
 in glucose intolerance, 71
- Oral contraceptives, and hyperlipidemia, 49
 and hypertension, 60-61
 health effects of, 145-152
- Organs, target, childhood changes in, 34
- Osler maneuver, for blood pressure measurement, 235-236
- Overdrive suppression, in prevention of tachycardias, 527
- Oxygenation, tissue, 201-207
- Pacemaker(s), antitachycardia, evaluation of, in children, 557
 long-term clinical experience with, 536
 dual-demand, 535
 escape, 389
 for termination of tachycardias, 528-533
 radiofrequency coupled, in termination of tachycardias, 535
- Pacemaker P cells, 401
- Pacing, antitachycardia, long-term, with implantable devices, 534
 atrial, accessory pathways and, 368-369
 and distal AV conduction system function, 422-423
 distal block induced by, 422
 in assessment of asymptomatic patients with positive exercise tolerance tests, 721
 incremental, 365-369
 automatic overdrive, in prevention of tachycardias, 527
 burst, subthreshold, 533
 overdrive, for ventricular tachycardia, 396
 vs. entrainment, 462
 underdrive, for ventricular tachycardia, 396
 in termination of tachycardias, 535
 ventricular, incremental, and atria, 375
- Pain, cardiac. See *Cardiac pain*.
 chest. See *Chest pain*.
- Parasympathetic blockade, 388
- Paroxysmal supraventricular tachycardia, digoxin for, 299
- Pathway conduction, slow- and fast-, 366
- Peak paced cycle length (PCLp), 402, 404
- Percutaneous Mapping and Ablation Registry, 544
- Peripheral vascular disease, in glucose intolerance, 71
- Personality, type A, as cardiovascular risk factor, 19-20
- Pharmacokinetics, definition of, 214
- Pharmacology. See also *Drug(s)* and names of specific drugs.
 geriatric clinical, 213-225
- Phenytoin, volume of distribution of, in elderly, 219-220
- Physical activity, as protective factor against cardiovascular disease, 20
- Physician-patient relationship, ethical issues in, 165-166
- Pindolol, and glucose intolerance, 128
- Plaque, arterial, in children, 34
- Plasma drug level(s), in ventricular tachycardia, 395
- Platelets, and atherogenesis, 9-10, 20
 in diabetes, 72
- Population attributable risk, in evaluation of risk factors, 7
- Postoverdrive suppression, 401
- Potassium balance, in elderly, 208-209
- Potassium-sparing diuretics, and glucose intolerance, 124
- Prazosin, and glucose intolerance, 127
 for hypertension, in elderly, 249-250
- Preexcitation, degree of, definition of, 448
 variants of, 454-455
- Preexcitation syndromes, classification of, 447-448
 electrophysiologic evaluation of, 354, 447-457
 history of, 447
- Proarrhythmia, definitions of, 488
 due to antiarrhythmic drugs, determination of, 488-495
 during electrophysiologic testing, incidence of, 489
 mechanisms underlying, 487-488
- Proarrhythmic effects, multiple, 494
- Proarrhythmic response(s), during electrophysiologic testing, 487-496
 unpredictability of, 495
- Probulol, and heart, 160
 and hyperlipidemia, 51
- Procainamide, for AV and AV nodal reentry, 444
 for stressing infranodal conduction system, 390
 for ventricular arrhythmias, 287-289
 for ventricular tachycardia, 396, 476
 electrophysiologic results of, 479-480
 incidence of proarrhythmia due to, 494
 in evaluation of distal AV conduction system, 423
- Progesterin, and hyperlipidemia, 49
 and hypertension, 60-61
 effects and health impacts of, 145-152
- Programmable stimulator, in electrophysiologic studies, 356-357
- Prolonged Q-T interval syndrome, in children, 559
- Propafenone, for ventricular tachycardia, electrophysiologic results of, 481
- Propranolol, and glucose intolerance, 127-128
 and hyperlipidemia, 50
 bioavailability of, 218-219
 for hypertrophic cardiomyopathy, 267
 for ventricular arrhythmias, in elderly, 293-294
 hepatic clearance of, in elderly, 216-217
- Propranolol resistance, aging and, 220-221
- Prostaglandins, and atherosclerosis, 20
- Public health, cardiovascular risk factors and, 4-8
- Public policy, ethical issues in, 166-167
- Pulmonary embolism, clinical and hemodynamic correlates in, 315-331
- Pulmonary toxicity, due to amiodarone, 295-296
- Pulmonic valve disease, in elderly, 270
- QRS complex, fully preexcited, 373
- Q-T interval, prolonged, syndrome of, in children, 559
- Quinidine, for arrhythmias, 285-287
 side effects of, 287
 for ventricular tachycardia, 396
 electrophysiologic results of, 480
 hepatic clearance of, in elderly, 218
 incidence of proarrhythmia due to, 494
- Quinidine-like drugs, in Wolff-Parkinson-White syndrome, 456
- Race, and cholesterol levels in children, 39
 and glucose intolerance, 69
 and hypertension, 59
 and left ventricular hypertrophy, 140
- Radiography, chest, for diagnosis of coronary artery disease, in elderly, 256
- Radionuclide angiography, exercise, in assessment of asymptomatic patients with positive exercise tolerance tests, 720
 in acute myocardial infarction, 507
- Radionuclide ventriculography, for detection of exercise-induced deterioration of regional myocardial function, 677-684

- Radionuclide ventriculography (*Continued*)
for detection of regional wall motion abnormalities, 682-683
for prognostic indicators after infarction, 655-656
Rate support, in prevention of tachycardias, 527
Reentry, atrioventricular, criteria for diagnosis of, 440-442
therapy for, 442-444
using concealed accessory pathway, 438-442
vs. AV nodal reentry, 442
atrioventricular nodal, 392
atypical, 438
criteria for diagnosis of, 435-438
therapy for, 442-444
typical, 432-438
vs. AV reentry, 442
bundle branch, 376
sinus node, 372
Refractoriness, homogenization of, in prevention of tachycardias, 527
sinus node, 412
Regional contraction abnormalities, as markers of myocardial ischemia, 682
Regional ejection fraction, during exercise, coronary arteriography in, 679
radionuclide data acquisition and analysis in, 677-679
to identify coronary artery disease, 677-684
Regional wall motion abnormalities, detection of, by radionuclide ventriculography, 682-683
Regression, logistic, in evaluation of cardiovascular risk factors, 5-6
Relative refractory period, of His-Purkinje system, 371
Renal drug clearance, in elderly, 214-216
changes in, 213-214
Renal function, in elderly, 227-234. See also *Kidney(s)*.
Renin-angiotensin system, in left ventricular hypertrophy, 88
Reperfusion arrhythmias, in sudden cardiac death, 602
Reproducibility, in electrophysiologic studies, 359
Respiratory mechanism(s), aging and, 201-202
Retinoids, and hyperlipidemia, 50
Retrograde block, in AV node, 374
in His-Purkinje system, 374
Retrograde effective refractory period, of sinus node, 412
Retrograde gap phenomenon, in His-Purkinje system, 376
Right ventricular dysplasia, arrhythmogenic, in children, 559
Risk, population attributable, in evaluation of cardiovascular risk factors, 7
Risk factors, cardiovascular, adverse effects of antihypertensive therapy on, 105-115
adverse effects of hyperlipidemic treatment on, 95-103
effects of hormonal therapy on, 145-152
identification and relative weight of, 3-32
modification of, ethical issues in, 163-168
reduction of, negative effects on heart, 153-161
risk of development of, and adverse effects of risk factor reduction, issue on, 3-168
Salt, dietary, and hypertension, 59-60
Secondary pauses, as manifestation of sinus node dysfunction, 388, 402, 404
Sedation, in children undergoing electrophysiologic study, 551-552
Sedimentation rate, erythrocyte, as cardiovascular risk factor, 20
Serum albumin concentration, changes in, in aging, 214
Serum cholesterol. See *Cholesterol*.
Sex, and glucose intolerance, 68-69
and left ventricular hypertrophy, 140
and obesity as cardiovascular risk factor, 77
Shock, cardiogenic, as complication of acute myocardial infarction, in elderly, 259
Sick sinus syndrome, in elderly, evaluation of, 275-278, 387-389
Silent myocardial ischemia, ambulatory electrocardiographic monitoring to assess therapy in, 632
and infarction, insights from Framingham study, 583-591. See also *Framingham Heart Study*.
as cause of ventricular tachyarrhythmias, 597-601
as mechanism of sudden cardiac death, 593-605
bradyarrhythmia and, 601
clinical implications of for physician, 748-750
definition and demonstration of, 577, 697
detection of, ambulatory monitoring in, technical considerations for, 629
exercise testing vs. ambulatory monitoring in, 627-628
in patients with effort angina, using continuous electrocardiographic monitoring, 627-633
detection, quantitation, and intervention of, potential of real-time processing of continuously monitored electrocardiogram in, 735-745
documentation of, methods of, 579
during daily activities, 635-642
electrocardiographic monitoring for, 595-600
exercise-induced, in asymptomatic persons, 708-711
incidence and significance of, after acute myocardial infarction, 651-653
in postinfarction period, diagnostic modalities for evaluation of, 653-656
in relation to acute myocardial infarction, 643-658
issue on, 577-750
left ventricular dysfunction and, 601
left ventricular dysfunction as manifestation of, 669-675. See *Ventricular dysfunction, left*.
localization of coronary artery stenoses in, with regional ejection fraction during exercise, 677-684
natural history of, 685-686
out-of-hospital ambulatory electrocardiography in, 659-668
possible mechanisms responsible for, 727-733
prevalence of, 577-579
prognostic and therapeutic implications of, 580, 617-620, 699-703
psychological ramifications of, 747-750
role of exercise testing in identification of, 705-715
scope of, 577-581
transient, mechanisms of, in ambulatory patients with effort angina, 631
treatment of, 685-696
coronary artery bypass surgery for, 692-693
pharmacologic agents in, 687-692
rationale for, 693-694
risk factor modification in, 686-687
stress and, 702
with transdermal nitroglycerin, 697-704
trigger factors for, 579-580
Sinoatrial conduction, 402
Sinoatrial conduction time, 354, 388, 405-412
as measure of sinus node function, 518
measurement of, atrial premature stimulation for, 405-410
Narula method for, 402, 410
Strauss method for, 405-410
Sinus arrhythmia, and atrial premature stimulation, 407
Sinus bradycardia, persistent, electrophysiologic evaluation of AV conduction system function in, 388

- Sinus nodal reentrant tachycardia, 430
- Sinus node, function of, electrophysiologic evaluation of, 401-416
- electrophysiologic testing vs. noninvasive testing of, 414
 - evaluation of, electrical activity in, 353-354
 - in syncope, 516-518
 - roles for electrophysiologic tests of, 412-414
 - vagal influences on, 404
 - refractoriness of, 412
- Sinus node disease, in children, electrophysiologic study of, 552-553
- Sinus node dysfunction, and ventricular tachycardia, 388
- dynamic electrocardiographic monitoring in, 387-388
 - evaluation of, 387-389
- Sinus node electrogram, techniques of, 410-412
- Sinus node entrance block, 372
- Sinus node recovery time (SNRT), 388, 401-405
- corrected, 388
 - definition of, 353
 - prolonged, clinical significance of, 517
- Sinus node reentry, 372
- Sinus node refractory period, as measure of sinus node function, 518
- studies of, 402
- Sinus recovery time (SRT), definition of, 402
- Sleep-related breathing disorder(s), aging and, 201-202
- hypertension and, in elderly, 206-207
- Smoking. See also *Tobacco*.
- as cardiovascular risk factor, 13, 18-19
 - cessation of, effect of, 8
 - effect on coronary artery disease, 257
- Snoring, hypertension and, 206
- Social support indicators, as cardiovascular risk factors, 19-20
- Socioeconomic factors, and hypertension, 61
- Sodium, dietary, and hypertension, 59-60
- Sodium balance, in elderly, 208-209
- Sodium metabolism, in elderly, 231
- Spironolactone, and glucose intolerance, 124
- Stimulation, multisite, in prevention of tachycardias, 528
- premature, atrial. See *Atrial premature stimulation*.
 - ventricular, 375-383
 - programmed electrical, 365
 - for reentrant supraventricular tachycardia, 392
 - for ventricular tachycardia, 473-475
 - in patients at risk for sudden cardiac death, 397-398
 - site and amplitude in, 475
 - technique of, 475
 - ultrarapid, single-capture train, 533
- Stimulation protocols, lack of uniformity in, 359-360
- Stimulus pulse, 465
- Strauss method, for measurement of sinoatrial conduction time, 402, 405-410
- Stress, and hypertension, 61
- as cardiovascular risk factor, 19-20
 - as factor in treatment of silent ischemia, 702
 - left ventricular wall, 84-86, 89
 - ventricular dysfunction during, in humans, 672-673
- Stroke, oral contraceptives and, 147-148
- risk of, in myocardial infarctions, in Framingham Heart Study, 587-588
- ST segment, ambulatory monitoring of, 660-665
- in normal populations, 661-662
 - in patients with coronary artery disease, 662-663
 - validation of with reference techniques, 664-665
 - as measure of myocardial ischemia, 660
- ST-segment depression, ischemic, frequency requirements for reproduction of, 629-631
- transient, as manifestation of reversible myocardial ischemia, 628-629
- ST-segment response, modifiers of, in exercise testing, 707
- ST-T-wave alterations, transient, relationship to coronary anatomy, 617-619
- Sudden cardiac death, arrhythmic mechanisms in, 594-600
- clinical antecedents of, 594
 - common substrates associated with, 594
 - coronary artery spasm and, 602
 - definition of, 593-594
 - dynamic electrocardiographic monitoring of patients at high risk for, 397
 - evaluation of patients at risk for, 355, 397-398
 - in children, ventricular arrhythmias and, 559
 - with Wolff-Parkinson-White syndrome, digitalis for prevention of, 557
 - in elderly, clinical presentation of, 254
 - morphologic findings in, and myocardial ischemia, 607-615
 - silent myocardial ischemia and, 593-605
- Supraventricular arrhythmia(s), in elderly, evaluation of, 278-279
- Supraventricular tachyarrhythmias, evaluation of, 354
- Supraventricular tachycardia, accessory pathway in, confirmation of, 453-454
- and syncope, 520-521
 - differential diagnosis of, 442
 - due to ectopic focus, 558
 - dynamic electrocardiographic monitoring in, 391
 - eccentric retrograde activation in, 453
 - evaluation of, 391-395
 - in children, electrophysiologic study of, 556-558
 - in electrophysiology laboratory, 533-534
 - in patients without overt preexcitation, 429-446
 - paroxysmal, 354
 - reentrant, 392
 - retrograde pathway used during, 392
- Syncope, and ventricular tachycardia, 521-523
- AV conduction in, evaluation of, 518-520
 - carotid hypersensitivity syndrome and, 520
 - causes of, 515-516
 - definition of, 515
 - evaluation of, ambulatory electrocardiographic monitoring in, 515
 - with electrophysiologic studies, 515-526
 - general indications for, 516
 - in chronic bifascicular block, 426
 - of undetermined etiology, evaluation of, 391
 - sinus node function in, evaluation of, 516-518
 - supraventricular tachycardia and, 520-521
 - unexplained, and chronic bifascicular block, 424
 - limitations of electrophysiologic studies in, 524-525
 - results of electrophysiologic studies in, 523-524
 - vasovagal, 515
- Systolic wall stress, of left ventricle, and hypertension, 84-86, 89
- Tachyarrhythmia(s). See specific types.
- Tachy-brady syndrome, 516. See also *Brady-tachy syndrome*.
- Tachycardia(s), acceleration of, in pacemaker termination of tachycardia, 532-533
- and hypertension, 61-62
 - atrial, 429-431
 - foci of, catheter ablation of, 546-548
 - atrioventricular reentrant, 392
 - automatic detection of, 535-536
 - catheter ablation for, 456
 - circus movement, 449

Tachycardia (*Continued*)

- detection of, algorithms for, 535-536
- drug-resistant, nonpharmacologic treatment of, 549
- induction of, reduction in number of extrastimuli required for, 492-494
- pacemaker termination of, 528-533
- paroxysmal supraventricular, digoxin for, 299
- prevention of, 527-528
- reentrant, termination of, by a single programmed extrastimulus, 529
- supraventricular. *See* *Supraventricular tachycardia*.
- termination of, implantable antitachycardia devices for, 535
 - methods of, 535
- ventricular. *See* *Ventricular tachycardia*.
- Tachycardia reentrant circuit, accessory pathway in, 453
- Tachycardia termination window, 529
- Tachycardia termination zone, 529
- Target organs, childhood changes in, 34
- Thallium-201 scintigraphy, in assessment of asymptomatic patients with positive exercise tolerance tests, 718-719
 - in assessment of perfusion abnormalities following exercise testing, 654-655
- Theophylline, hepatic clearance of, in elderly, 218
- Thiazide diuretics, and glucose intolerance, 120-123
 - for hypertension, in elderly, 247-248
- Thromboembolism, oral contraceptives and, 147-148
- Thrombosis, and atherogenesis, 9-10
- Thrombotic tendencies, and cardiovascular risk factors, 20-21
- Timolol, and glucose intolerance, 128
- Tissue oxygenation, in elderly, 201-207
- Tobacco. *See also* *Smoking*.
 - and hypertension, 60
- Tocainide, for ventricular arrhythmias, in elderly, 291
 - for ventricular tachycardia, electrophysiologic results of, 480
 - incidence of proarrhythmia due to, 494
- Torsades de pointes, 487
- Total body drug clearance, in elderly, 214
- Total recovery time. *See also* *Entire recovery time*.
 - in electrophysiologic evaluation of sinus node dysfunction, 388
- Tract, accessory pathway known as, in preexcitation, 448
- Transluminal coronary angioplasty, in elderly, 309-310
- Transtelephone monitoring, and tachycardia, 535
- Triamterene, and glucose intolerance, 124
- Tricuspid valve disease, in elderly, 269
- Trifascicular block, 417, 424
- Triglycerides, as cardiovascular risk factor, 17-18
 - obesity and, 75-76
 - reduction of, adverse effects of, 95-103
- Type A personality, as cardiovascular risk factor, 19-20
- Unifascicular block, 417
- Valvular heart disease, in elderly, 263-271
- Vasculature, role of, in regulation of cardiac output, 333-345
- Vasodepressor syndrome, in elderly, 281
- Vasodilators, and glucose intolerance, 127
- Vegetarian diet, as protective factor against cardiovascular disease, 21-22
- Venous thrombosis, in electrophysiologic studies, 357
- Ventricle, left, hypertrophy of. *See* *Left ventricular hypertrophy*.
 - wall stress of, and hypertension, 84-86, 89
- Ventricular arrhythmia(s), and sudden death, in children, 559
 - in children, electrophysiologic study of, 558-561
 - in elderly, evaluation of, 279-280
 - mapping of, 497-505. *See also* *Mapping*.
 - myocardial injury in development of, 459-461
 - prognostic risk of, 566
 - prospective evaluation of, using electrophysiologic techniques, 507-513
 - therapy for, 566
 - types of, 566
- Ventricular drive rates, 465-466
- Ventricular dysfunction, left, acute ischemic, animal
 - models of, 669-670
 - in humans, 670-672
 - as manifestation of silent myocardial ischemia, 669-675
 - during stress, in humans, 672-673
 - silent ischemia-mediated, pharmacologic and revascularization-related evidence for, 673-674
- Ventricular ectopic activity, complex, programmed stimulation for, 398
- Ventricular electrical stimulation, in humans, normal and abnormal responses to, 463-465
- Ventricular extrastimulus studies, in children, 560
- Ventricular fibrillation, and pleomorphic ventricular tachycardia, 464
 - definition of, 463
 - in sudden cardiac death syndrome, 355
 - in syncope, 522
- Ventricular myocardium, 375-376
- Ventricular preexcitation, 447
- Ventricular premature stimulation, 375-383
- Ventricular response, repetitive, 464-465
 - definition of, 463
 - in acute myocardial infarction, 507
- Ventricular septal defect, as complication of acute myocardial infarction, 260
- Ventricular tachyarrhythmia(s), evaluation of, 354-355
 - malignant, evaluation of patients at risk for, 355
 - silent ischemia as cause of, 597-601
- Ventricular tachycardia, activation sequence in, 462-463
 - amiodarone for, 396
 - ability of electrophysiologic tests to predict prognosis in, 482-483
 - and mapping, 501-503
 - and sinus node dysfunction, 388
 - and syncope, 521-523
 - antiarrhythmic agents for, 476-477
 - electrophysiologic results of, 477-483
 - benefits of electrophysiologically directed pharmacologic therapy for, 478-479
 - catheter ablation for, 548, 549
 - electrophysiologic stimulation protocol prior to antiarrhythmic medication, 475
 - foci of, catheter ablation of, 548
 - general concepts and mechanisms of, 459-472
 - hemodynamically stable, conversion of, to tachyarrhythmia requiring cardioversion, 492
 - in electrophysiology laboratory, 534
 - in sudden cardiac death syndrome, 355
 - induced nonsustained, conversion of, to sustained ventricular tachycardia, 489-490
 - maps for, 497-501
 - monomorphic, definition of, 463
 - multiple-morphology, and mapping, 503
 - noninducible, and mapping, 503
 - nonsustained, 464
 - pharmacologic therapy for, 475-477
 - using electrophysiologic techniques, 473-486
 - pleomorphic, and ventricular fibrillation, 464

- polymorphic, definition of, 463
 - in syncope, 522
- programmed stimulation for, 473-475
- recurrent sustained, evaluation of, 395-397
- reproducibility of, 467
- specificity of, 474
- stimulation of, techniques for, 465-467
- sustained, definition of, 395, 463
- sustained unimorphic, 463-464
- synchronized transvenous cardioversion of, 536
- unsustained, definition of, 463
- Ventriculoatrial (VA) conduction, 373
- Ventriculography, radionuclide. See *Radionuclide ventriculography*.
- Verapamil, for angina, in elderly, 257
 - for AV and AV nodal reentry, 444
 - for supraventricular arrhythmias, in elderly, 297-298
 - in Wolff-Parkinson-White syndrome, 455
 - incidence of proarrhythmia due to, 494
- Wall motion abnormalities, regional, detection of, by radionuclide ventriculography, 682-683
- Wall stress, left ventricular, and hypertension, 84-86, 89
- Water metabolism, in elderly, 230-231
- Wenckebach periodicity, 374, 389
- Wenckebach phenomenon, AV nodal, 366
 - in His-Purkinje system, 368, 375
- Wolff-Parkinson-White syndrome, accessory pathway in, 373
 - latent, 450
 - amiodarone for, 456
 - and supraventricular tachycardia, 393-394
 - digoxin for, 299
 - electrocardiographic manifestations of, 448-449
 - electrophysiologic evaluation of, 447-454
 - electrophysiologic evaluation of pharmacologic therapy of arrhythmias complicating, 455-456
 - evaluation of pacemaker and surgical therapy of arrhythmias complicating, 456
 - in children, digitalis for, 557
 - incidence of tachyarrhythmias in, 449
 - mechanisms of supraventricular tachycardia in, 449-450
 - supraventricular tachyarrhythmias in, 354
 - tachycardias accompanying, 453
 - therapy for, 393-394
- Zone of full compensation, 372
- Zone of reset, 372